RxDoctor Payments Data

Kenneth Abriola, MD

Internal Medicine · Glastonbury, CTNPI 1083693022

Payments from drug & device makers

$1,344in general payments, 2019–2025

Across 42 payments — averaging $31.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$497
  • Viiv Healthcare Company$258
  • Theratechnologies Inc.$204
  • Janssen Products, LP$191
  • Insmed, Inc.$103
  • Johnson & Johnson$79
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$1,23292%
  • Education$1128%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,344 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$21,868
Medicare patients
73
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala261$1,299,465
DescovyEmtricitabine/Tenofov Alafenam70$184,491
GenvoyaElviteg/Cob/Emtri/Tenof Alafen34$175,727
TriumeqAbacavir/Dolutegravir/Lamivudi41$168,528
OdefseyEmtricitab/Rilpiviri/Tenof Ala33$123,082
TivicayDolutegravir Sodium49$111,084
OzempicSemaglutide98$101,493
PrezcobixDarunavir/Cobicistat41$99,800
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf16$79,118
PifeltroDoravirine26$45,982
CompleraEmtricita/Rilpivirine/Tenof Df11$37,996
DovatoDolutegravir Sodium/Lamivudine11$37,616
JardianceEmpagliflozin21$29,704
Darunavir22$22,471
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df13$18,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$497$1,659,682365 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato$258$317,227101 claims
Johnson & JohnsonPrezcobix, Complera$79$137,79652 claims
Janssen Products, LPSymtuza$191$79,11816 claims
MerckPifeltro, Janumet$13$53,76141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Glastonbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →